Glen Tullman’s healthcare startup Livongo Health just raised a huge new round of funding to grow its business.
Livongo, a startup focused on diabetes and other chronic health conditions, announced Wednesday that it has raised $105 million in new funding, led by previous investors General Catalyst and Kinnevik. Other investors in the round include existing investors DFJ, Kleiner Perkins Caufield & Byers, Merck Global Health Innovation Fund, Microsoft Ventures, Sapphire Ventures, Zaffre Investments and 7wire Ventures. New investor Echo Health Ventures also invested in the round.
Livongo is based in Mountain View but has a large second office in Chicago. The startup, founded in 2014, has around 70 employees in Chicago and continues to grow its team here, a spokesperson said. Tullman, the former CEO of Allscripts and the brother of former 1871 CEO Howard Tullman, is based in Chicago.
Livongo has now raised more than $240 million to date. It last raised $52 million in March 2017.
Livongo makes a blood glucose monitor and digital dashboard to help people better manage their diabetes. The startup’s glucose meter connects to the cloud to give people real-time information on their blood sugar, and it can send patient information to doctors and their loved ones.
Livongo also announced a strategic partnership Wednesday with Oregon-based Cambia Health Solutions to provide its diabetes solution to the health system’s patients.
“We are particularly pleased with the strong vote of confidence from the marketplace for Livongo,” Tullman said in a statement. “With a blue-chip client base including more than 350 of the country’s largest self-insured employers, the most innovative health systems and health plans, and the two largest pharmacy benefit managers combined with the leading investors in healthcare, we are positioned to significantly accelerate our growth.”